Vaccines, Combined
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses